Communiqués EDAP TMS S.A.

Actions

FOCL

US2683111072

Equipement et technologie médicale avancés

Temps Différé Nasdaq 15:44:30 27/08/2026			Varia. 5j.	Varia. 1 janv.
4,478 ^USD	+1,53%		+5,60%	+36,10%

25/08	Légère hausse des actions européennes cotées aux États-Unis sous forme d'ADR lors de la séance de mardi	MT
21/08	Les actions européennes cotées aux États-Unis sous forme d'ADR s'inscrivent en hausse lors de la séance de vendredi	MT

Communiqués

13/08	FocalTherics™ Reports Second Quarter 2026 Financial Results	GL
12/08	FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares	GL
12/08	FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares	AQ
11/08	FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026	GL
11/08	FocalTherics™ Announces Proposed Public Offering of American Depositary Shares	GL
30/07	FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026	GL
30/06	FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients	GL
16/06	FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical	GL
29/05	EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy	AQ
29/05	EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy	GL
21/05	EDAP \| Focal One to Present at Jefferies 2026 Global Healthcare Conference	GL
14/05	EDAP \| Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer	GL
13/05	EDAP \| Focal One to Host Investor Day on June 1, 2026	GL
07/05	EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue	AQ
07/05	EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue	GL
30/04	EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer	GL
16/04	EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026	GL
25/03	EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue	GL
10/03	EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference	GL
04/03	EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026	GL
12/02	EDAP Announces Appointment of David Horn to Board of Directors	GL
12/01	EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance	GL
20/11	EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU	GL
18/11	EDAP to Present at Piper Sandler 37th Annual Healthcare Conference	GL
06/11	EDAP Reports Third Quarter 2025 Financial Results	GL